Clinical Trial

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Study acronym: MASCOT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
Protocol Amendment History 2 changes
minor Trial arms changed: 3 -> 2 2026-06-05
notable Enrollment increased: 357 -> 401 participants 2026-04-24
Trial Details
NCT Number NCT06706622
Lead Sponsor H. Lundbeck A/S
Conditions Multiple System Atrophy
Enrollment 401 participants
Start Date 2024-12-03
Primary Completion 2028-02-17 (estimated)
Study Completion 2029-10-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-14